Stockreport

Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Mal...

Dr. Reddy's Laboratories Ltd  (RDY) 
US:NYSE Investor Relations: drreddys.com/investors
PDF BANGALORE, India--(BUSINESS WIRE)--Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology, today announced init [Read more]